Larotrectinib has been launched in China and is suitable for NTRK gene fusion positive solid tumor patients. The product name is "Vitrakvi" and should be purchased through formal channels while paying attention to the quality of the drug.

1. Listing Information

(1) Larotinib was approved for market by the China National Medical Products Administration in April 2022, and is the first broad-spectrum anti-cancer targeted drug in China targeting NTRK gene fusion.

(2) This drug is developed by Bayer and belongs to the TRK inhibitor class, which can penetrate the blood-brain barrier.

Scope of indications 2

(1) Used for treating adult and pediatric solid tumor patients carrying NTRK gene fusion, regardless of tumor type.

(2) Clinical data shows that it is effective for various types of tumors such as lung cancer, thyroid cancer, and sarcoma.

3 Medication precautions

(1) The NTRK gene fusion must be confirmed positive through genetic testing before it can be used.

(2) When purchasing, one should choose a reputable medical institution and verify the drug approval number and production batch number.

(3) It should be used under the guidance of a professional doctor and attention should be paid to monitoring adverse reactions in the nervous system.